Brokerages Set ADMA Biologics Inc (NASDAQ:ADMA) Target Price at $28.00
by Doug Wharley · The Cerbat GemADMA Biologics Inc (NASDAQ:ADMA – Get Free Report) has earned a consensus rating of “Buy” from the five analysts that are currently covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $28.00.
A number of research firms have weighed in on ADMA. Zacks Research raised shares of ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 2nd. Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a report on Tuesday, December 23rd. Cantor Fitzgerald restated a “neutral” rating on shares of ADMA Biologics in a report on Thursday, March 26th. Wall Street Zen downgraded shares of ADMA Biologics from a “buy” rating to a “hold” rating in a report on Saturday. Finally, Mizuho dropped their price objective on shares of ADMA Biologics from $30.00 to $24.00 and set an “outperform” rating on the stock in a report on Monday, April 13th.
ADMA Biologics Price Performance
ADMA Biologics stock opened at $11.01 on Monday. The firm has a market cap of $2.62 billion, a price-to-earnings ratio of 18.35 and a beta of 0.82. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.71 and a quick ratio of 3.74. ADMA Biologics has a fifty-two week low of $7.21 and a fifty-two week high of $25.67. The firm has a fifty day moving average price of $13.45 and a two-hundred day moving average price of $15.81.
ADMA Biologics (NASDAQ:ADMA – Get Free Report) last released its earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.20. The firm had revenue of $139.16 million during the quarter, compared to analyst estimates of $139.80 million. ADMA Biologics had a net margin of 28.80% and a return on equity of 37.52%. The business’s revenue was up 18.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.46 EPS. As a group, analysts forecast that ADMA Biologics will post 0.51 earnings per share for the current year.
Insider Activity
In other news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the business’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $15.63, for a total transaction of $157,800.48. Following the transaction, the chief operating officer owned 466,600 shares in the company, valued at approximately $7,292,958. The trade was a 2.12% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Steve Elms bought 7,000 shares of the stock in a transaction that occurred on Thursday, March 5th. The stock was acquired at an average cost of $15.67 per share, for a total transaction of $109,690.00. Following the purchase, the director owned 2,038,730 shares of the company’s stock, valued at $31,946,899.10. This trade represents a 0.34% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 3.50% of the company’s stock.
Institutional Trading of ADMA Biologics
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Salomon & Ludwin LLC bought a new stake in ADMA Biologics in the third quarter valued at about $25,000. Rothschild Investment LLC increased its stake in ADMA Biologics by 373.8% in the third quarter. Rothschild Investment LLC now owns 1,895 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 1,495 shares during the period. Summit Securities Group LLC bought a new stake in ADMA Biologics in the fourth quarter valued at about $29,000. Clearstead Advisors LLC increased its stake in ADMA Biologics by 55.7% in the third quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 795 shares during the period. Finally, iSAM Funds UK Ltd bought a new stake in ADMA Biologics in the third quarter valued at about $34,000. Institutional investors own 75.68% of the company’s stock.
About ADMA Biologics
ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.
The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.